Guiyang Xintian Pharmaceutical Co Ltd
SZSE:002873
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Guiyang Xintian Pharmaceutical Co Ltd
SZSE:002873
|
CN |
|
W
|
Welspun Enterprises Ltd
NSE:WELENT
|
IN |
|
K
|
Kip Real Estate Investment Trust
KLSE:KIPREIT
|
MY |
Bankruptcy Probability
Guiyang Xintian Pharmaceutical Co Ltd's probability of bankruptcy is 2.2%, pointing to a small but noticeable default risk. The solvency score is 57/100 — a warning sign of potential financial weakness.
We take all the information about a company's solvency (such as how easily a company can pay interest on its outstanding debt, how much cash it has, the amount of debt, and more) and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Guiyang Xintian Pharmaceutical Co Ltd Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CN |
|
Guiyang Xintian Pharmaceutical Co Ltd
SZSE:002873
|
2.7B CNY |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
900.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
581B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236B GBP |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
304.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
229.9B CHF |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
156.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Guiyang Xintian Pharmaceutical Co Ltd's probability of bankruptcy is 2.2%, pointing to a small but noticeable default risk.
The probability of bankruptcy is estimated using credit risk models that assess its financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Guiyang Xintian Pharmaceutical Co Ltd has total debt of 522.6m CNY. This includes both short-term (95.9m CNY) and long-term (426.8m CNY) debt.
You can find a full breakdown on its Balance Sheet.
